메뉴 건너뛰기




Volumn 58, Issue 1, 1999, Pages 1-27

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy

Author keywords

AIDS; Combination therapy; HIV resistance; Non nucleoside RT inhibitors (NNRTIs); Nucleoside RT inhibitors (NRTIs); Reverse transcriptase (RT)

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; PYRIDONE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TALVIRALINE; TENOFOVIR; TIPRANAVIR; TROVIRDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

EID: 0033169086     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00029-5     Document Type: Note
Times cited : (79)

References (219)
  • 1
    • 0029815914 scopus 로고    scopus 로고
    • Analysis of inhibition of retroviral reverse transcriptase
    • Balzarini J and De Clercq E, Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol 275: 472-502, 1996.
    • (1996) Methods Enzymol , vol.275 , pp. 472-502
    • Balzarini, J.1    De Clercq, E.2
  • 2
    • 0001178693 scopus 로고    scopus 로고
    • Biochemical pharmacology of nucleoside and non-nucleoside reverse transcriptase inhibitors active against HIV
    • Eds. Merigan TC, Bartlett JG and Bolognesi D, Chap. 47, Williams & Wilkins, Baltimore, MD
    • Balzarini J and De Clercq E, Biochemical pharmacology of nucleoside and non-nucleoside reverse transcriptase inhibitors active against HIV. In: Textbook of AIDS Medicine (Eds. Merigan TC, Bartlett JG and Bolognesi D), Chap. 47, pp. 815-847. Williams & Wilkins, Baltimore, MD, 1998.
    • (1998) Textbook of AIDS Medicine , pp. 815-847
    • Balzarini, J.1    De Clercq, E.2
  • 3
    • 0028924567 scopus 로고
    • Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
    • Esnouf R, Ren JS, Ross C, Jones Y, Stammers D and Stuart D, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-308, 1995.
    • (1995) Nat Struct Biol , vol.2 , pp. 303-308
    • Esnouf, R.1    Ren, J.S.2    Ross, C.3    Jones, Y.4    Stammers, D.5    Stuart, D.6
  • 4
    • 0028925773 scopus 로고
    • Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
    • Spence RA, Kati WM, Anderson KS and Johnson KA, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 267: 988-993, 1995.
    • (1995) Science , vol.267 , pp. 988-993
    • Spence, R.A.1    Kati, W.M.2    Anderson, K.S.3    Johnson, K.A.4
  • 5
    • 0028120730 scopus 로고
    • HIV resistance to reverse transcriptase inhibitors
    • De Clercq E, HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 47: 155-169, 1994.
    • (1994) Biochem Pharmacol , vol.47 , pp. 155-169
    • De Clercq, E.1
  • 6
    • 0029011730 scopus 로고
    • Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
    • De Clercq E, Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 38: 2491-2517, 1995.
    • (1995) J Med Chem , vol.38 , pp. 2491-2517
    • De Clercq, E.1
  • 7
    • 0028922944 scopus 로고
    • Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different medianistic forms of the enzyme
    • Fletcher RS, Syed K, Mithani S, Dmitrienko GI and Parniak MA, Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different medianistic forms of the enzyme. Biochemistry 34: 4346-4353, 1995.
    • (1995) Biochemistry , vol.34 , pp. 4346-4353
    • Fletcher, R.S.1    Syed, K.2    Mithani, S.3    Dmitrienko, G.I.4    Parniak, M.A.5
  • 8
    • 0029153101 scopus 로고
    • Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide non-nucleoside compounds
    • Fletcher RS, Arion D, Borkow G, Wainberg MA, Dmitrienko GI and Pamiak MA, Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide non-nucleoside compounds. Biochemistry 34: 10106-10112, 1995.
    • (1995) Biochemistry , vol.34 , pp. 10106-10112
    • Fletcher, R.S.1    Arion, D.2    Borkow, G.3    Wainberg, M.A.4    Dmitrienko, G.I.5    Pamiak, M.A.6
  • 9
    • 0029922342 scopus 로고    scopus 로고
    • Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine
    • Balzarini J, Pelemans H, Pérez-Pérez M-J, San-Félix A, Camarasa M-J, De Clercq E and Karlsson A, Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol Pharmacol 49: 882-890, 1996.
    • (1996) Mol Pharmacol , vol.49 , pp. 882-890
    • Balzarini, J.1    Pelemans, H.2    Pérez-Pérez, M.-J.3    San-Félix, A.4    Camarasa, M.-J.5    De Clercq, E.6    Karlsson, A.7
  • 10
    • 0029822057 scopus 로고    scopus 로고
    • Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors
    • Balzarini J, Pelemans H, Karlsson A, De Clercq E and Kleim J-P, Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Nad Acad Sci USA 93: 13152-13157, 1996.
    • (1996) Proc Nad Acad Sci USA , vol.93 , pp. 13152-13157
    • Balzarini, J.1    Pelemans, H.2    Karlsson, A.3    De Clercq, E.4    Kleim, J.-P.5
  • 11
    • 0013577776 scopus 로고
    • Mutational analysis of the saquinavir high dose monotherapy study
    • Sardinia, Italy, 6-9 July, Abstract No. 73
    • Schapiro JM, Winters M and Merigan TC, Mutational analysis of the saquinavir high dose monotherapy study. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 73.
    • (1995) Fourth Int Workshop on HIV Drug Resistance
    • Schapiro, J.M.1    Winters, M.2    Merigan, T.C.3
  • 15
    • 0027363224 scopus 로고
    • Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus
    • Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J and De Clercq E, Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196: 576-585, 1993.
    • (1993) Virology , vol.196 , pp. 576-585
    • Balzarini, J.1    Karlsson, A.2    Pérez-Pérez, M.-J.3    Camarasa, M.-J.4    De Clercq, E.5
  • 16
    • 0026693137 scopus 로고
    • Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
    • Kohlstaedt LA, Wang J, Friedman JM, Rice PA and Steitz TA, Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790, 1992.
    • (1992) Science , vol.256 , pp. 1783-1790
    • Kohlstaedt, L.A.1    Wang, J.2    Friedman, J.M.3    Rice, P.A.4    Steitz, T.A.5
  • 22
    • 0029645409 scopus 로고
    • The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design
    • Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D and Stuart D, The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 3: 915-926, 1995.
    • (1995) Structure , vol.3 , pp. 915-926
    • Ren, J.1    Esnouf, R.2    Hopkins, A.3    Ross, C.4    Jones, Y.5    Stammers, D.6    Stuart, D.7
  • 25
    • 0030935265 scopus 로고    scopus 로고
    • Unique features in the struture of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
    • Esnouf RM, Ren J, Hopkins AL, Ross AK, Jones EY, Stammers DK and Stuart DI, Unique features in the struture of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Nad Acad Sci USA 94: 3984-3989, 1997.
    • (1997) Proc Nad Acad Sci USA , vol.94 , pp. 3984-3989
    • Esnouf, R.M.1    Ren, J.2    Hopkins, A.L.3    Ross, A.K.4    Jones, E.Y.5    Stammers, D.K.6    Stuart, D.I.7
  • 26
  • 27
    • 34250082672 scopus 로고
    • Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design
    • Nanni RG, Ding J, Jacobo-Molina A, Hughes SH and Arnold E, Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect Drug Discov Des 1: 129-150, 1993.
    • (1993) Perspect Drug Discov Des , vol.1 , pp. 129-150
    • Nanni, R.G.1    Ding, J.2    Jacobo-Molina, A.3    Hughes, S.H.4    Arnold, E.5
  • 33
    • 0013608579 scopus 로고    scopus 로고
    • Structures of Met184Ile and Met184Val mutants of HIV-1 reverse transcriptase with and without bound nucleic acid reveal template-primer repositioning and steric hindrance mechanism for lamivudine resistance
    • Lake Maggiore, Italy, 24-27 June, Abstract No. 22
    • Sarafianos SG, Kas K, Ding J, Clark AD Jr, Boyer PL, Hughes SH and Arnold E, Structures of Met184Ile and Met184Val mutants of HIV-1 reverse transcriptase with and without bound nucleic acid reveal template-primer repositioning and steric hindrance mechanism for lamivudine resistance. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 22.
    • (1998) Second Int Workshop on HIV Drug Resistance and Treatment Strategies
    • Sarafianos, S.G.1    Kas, K.2    Ding, J.3    Clark A.D., Jr.4    Boyer, P.L.5    Hughes, S.H.6    Arnold, E.7
  • 36
    • 18744428228 scopus 로고    scopus 로고
    • Antiviral activity of the human immunodeficiency virus type 1 specific non-nucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study
    • Kleim J-P, Winters M, Dunkler A, Suarez J-R, Riess G, Winkler I, Balzarini J, Oette D and Merigan T, Antiviral activity of the human immunodeficiency virus type 1 specific non-nucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. J Inject Dis 179: 709-713, 1999.
    • (1999) J Inject Dis , vol.179 , pp. 709-713
    • Kleim, J.-P.1    Winters, M.2    Dunkler, A.3    Suarez, J.-R.4    Riess, G.5    Winkler, I.6    Balzarini, J.7    Oette, D.8    Merigan, T.9
  • 39
    • 0026052102 scopus 로고
    • Chimeric human immunodeficiency virus type-1/type-2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors
    • Shih C-K, Rose JM, Hansen GL, Wu JC, Bacolla A and Griffin JA, Chimeric human immunodeficiency virus type-1/type-2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88: 9878-9882, 1991.
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 9878-9882
    • Shih, C.-K.1    Rose, J.M.2    Hansen, G.L.3    Wu, J.C.4    Bacolla, A.5    Griffin, J.A.6
  • 40
    • 0026662959 scopus 로고
    • The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2
    • Shaharabany M and Hizi A, The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J Biol Chem 267: 3674-3678, 1992.
    • (1992) J Biol Chem , vol.267 , pp. 3674-3678
    • Shaharabany, M.1    Hizi, A.2
  • 41
    • 0000342562 scopus 로고    scopus 로고
    • Mutations in retroviral genes associated with drug resistance
    • Schinazi RF, Larder Ba and Mellors JW, Mutations in retroviral genes associated with drug resistance. Int Antiviral News 5: 129, 1997.
    • (1997) Int Antiviral News , vol.5 , pp. 129
    • Schinazi, R.F.1    Larder, B.A.2    Mellors, J.W.3
  • 42
    • 0002689509 scopus 로고    scopus 로고
    • Resistance tables for antiretroviral drugs
    • Menéndez-Arias L and Domingo E, Resistance tables for antiretroviral drugs. AIDS Cyber J 1: 95-127, 1998.
    • (1998) AIDS Cyber J , vol.1 , pp. 95-127
    • Menéndez-Arias, L.1    Domingo, E.2
  • 43
    • 0030754485 scopus 로고    scopus 로고
    • Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: How to prevent the problem?
    • De Clercq E, Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: How to prevent the problem? Int J Antimicrob Agents 9: 21-36, 1997.
    • (1997) Int J Antimicrob Agents , vol.9 , pp. 21-36
    • De Clercq, E.1
  • 44
    • 0030708683 scopus 로고    scopus 로고
    • Search of a selective antiviral chemotherapy
    • De Clercq E, In Search of a selective antiviral chemotherapy. Clin Microbiol Rev 10: 674-693, 1997.
    • (1997) Clin Microbiol Rev , vol.10 , pp. 674-693
    • De Clercq, E.1
  • 45
    • 0029877789 scopus 로고    scopus 로고
    • Non-nucleoside reverse transcriptase inhibitors (NNRTIs for the treatment of human immunodeficiency virus type 1 (HIV-1 infections: Strategies to overcome drug resistance development
    • De Clercq E, Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. Med Res Rev 16: 125-157, 1996.
    • (1996) Med Res Rev , vol.16 , pp. 125-157
    • De Clercq, E.1
  • 46
    • 0028323494 scopus 로고
    • Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
    • Larder BA, Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 75: 951-957, 1994.
    • (1994) J Gen Virol , vol.75 , pp. 951-957
    • Larder, B.A.1
  • 47
    • 0030847952 scopus 로고    scopus 로고
    • Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice
    • Moyle GJ, Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 6: 943-964, 1997.
    • (1997) Exp Opin Invest Drugs , vol.6 , pp. 943-964
    • Moyle, G.J.1
  • 49
    • 0032173626 scopus 로고    scopus 로고
    • New antivirals-mechanism of action and resistance development
    • Balzarini J, Naesens L and De Clercq E, New antivirals-mechanism of action and resistance development. Curr Opin Microbiol 1: 535-546, 1998.
    • (1998) Curr Opin Microbiol , vol.1 , pp. 535-546
    • Balzarini, J.1    Naesens, L.2    De Clercq, E.3
  • 50
    • 0024310253 scopus 로고
    • Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
    • Larder BA and Kemp SD, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158, 1989.
    • (1989) Science , vol.246 , pp. 1155-1158
    • Larder, B.A.1    Kemp, S.D.2
  • 51
    • 0026042638 scopus 로고
    • Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture
    • Larder BA, Coates KE and Kemp SD, Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 65: 5232-5236, 1991.
    • (1991) J Virol , vol.65 , pp. 5232-5236
    • Larder, B.A.1    Coates, K.E.2    Kemp, S.D.3
  • 52
    • 0026565278 scopus 로고
    • Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
    • Kellam P, Boucher CA and Larder BA, Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934-1938, 1992.
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 1934-1938
    • Kellam, P.1    Boucher, C.A.2    Larder, B.A.3
  • 53
    • 0028031833 scopus 로고
    • Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
    • Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS and D'Aquila RT, Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38: 282-287, 1994.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 282-287
    • Zhang, D.1    Caliendo, A.M.2    Eron, J.J.3    DeVore, K.M.4    Kaplan, J.C.5    Hirsch, M.S.6    D'Aquila, R.T.7
  • 54
    • 0028057581 scopus 로고
    • Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine
    • Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J and Wainberg MA, Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 38: 275-281, 1994.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 275-281
    • Gu, Z.1    Gao, Q.2    Fang, H.3    Salomon, H.4    Parniak, M.A.5    Goldberg, E.6    Cameron, J.7    Wainberg, M.A.8
  • 56
    • 0002191642 scopus 로고    scopus 로고
    • K65R mutation in HIV-1 reverse transcriptase causes resistance to (-)β-D-dioxolane-guanosine and reverses AZT resistance
    • Whistler, Canada, 3-6 July, Abstract No. 7
    • Mellors JW, Bazmi H, Chu CK and Schinazi RF, K65R mutation in HIV-1 reverse transcriptase causes resistance to (-)β-D-dioxolane-guanosine and reverses AZT resistance. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 7.
    • (1996) Fifth Int Workshop on HIV Drug Resistance
    • Mellors, J.W.1    Bazmi, H.2    Chu, C.K.3    Schinazi, R.F.4
  • 57
  • 60
    • 0013580709 scopus 로고
    • Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89)
    • American Society for Microbiology Washington, DC, Abstract No. 182
    • Tisdale M, Parry NR, Cousens D, St. Clair MH and Boone LR, Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89). 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, 1994, Abstract No. 182, p. 92.
    • (1994) 34th Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 92
    • Tisdale, M.1    Parry, N.R.2    Cousens, D.3    St. Clair, M.H.4    Boone, L.R.5
  • 61
    • 0030945276 scopus 로고    scopus 로고
    • Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
    • Tisdale M, Alnadaf T and Cousens D, Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 41: 1094-1098, 1997.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1094-1098
    • Tisdale, M.1    Alnadaf, T.2    Cousens, D.3
  • 62
    • 0003213577 scopus 로고    scopus 로고
    • Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89
    • and CNAA2001 Trial Team, 22-26 January, Washington, DC, USA, Abstract No. 15
    • Harrigan R, Stone C, Griffin P, Bloor S, Tisdale M, Larder B and CNAA2001 Trial Team, Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89. Fourth Conference on Retroviruses and Opportunistic Infections, 22-26 January 1997, Washington, DC, USA, Abstract No. 15.
    • (1997) Fourth Conference on Retroviruses and Opportunistic Infections
    • Harrigan, R.1    Stone, C.2    Griffin, P.3    Bloor, S.4    Tisdale, M.5    Larder, B.6
  • 64
    • 0029795423 scopus 로고    scopus 로고
    • Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers deceased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro
    • Cherrington JM, Mulato AS, Fuller MD and Chen MS, Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers deceased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 40: 2212-2216, 1996.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 2212-2216
    • Cherrington, J.M.1    Mulato, A.S.2    Fuller, M.D.3    Chen, M.S.4
  • 65
    • 0003214068 scopus 로고    scopus 로고
    • Genotypic characterization of HIV-1 variants isolated from AIDS patients treated with adefovir dipivoxil (bis-POM PMEA)
    • St. Petersburg, Florida, USA, 25-28 June, Abstract No. 24
    • Mulato A, Lamy P, Li W, Miller M and Cherrington J, genotypic characterization of HIV-1 variants isolated from AIDS patients treated with adefovir dipivoxil (bis-POM PMEA). Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 24.
    • (1997) Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication
    • Mulato, A.1    Lamy, P.2    Li, W.3    Miller, M.4    Cherrington, J.5
  • 67
    • 0028332029 scopus 로고
    • Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
    • Lacey SF and Larder BA, Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 38: 1428-1432, 1994.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 1428-1432
    • Lacey, S.F.1    Larder, B.A.2
  • 70
    • 0026465275 scopus 로고
    • Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine
    • Gu Z, Gao Q, Li X, Parniak MA and Wainberg MA, Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 66: 7128-7135, 1992.
    • (1992) J Virol , vol.66 , pp. 7128-7135
    • Gu, Z.1    Gao, Q.2    Li, X.3    Parniak, M.A.4    Wainberg, M.A.5
  • 72
    • 0027285372 scopus 로고
    • Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
    • Tisdale M, Kemp SD, Parry NR and Larder BA, Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90: 5653-5656, 1993.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 5653-5656
    • Tisdale, M.1    Kemp, S.D.2    Parry, N.R.3    Larder, B.A.4
  • 75
    • 0027155374 scopus 로고
    • The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine
    • Gao Q, Gu Z, Pamiak MA, Cameron J, Cammack N, Boucher C and Wainberg MA, The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37: 1390-1392, 1993.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1390-1392
    • Gao, Q.1    Gu, Z.2    Pamiak, M.A.3    Cameron, J.4    Cammack, N.5    Boucher, C.6    Wainberg, M.A.7
  • 76
    • 0030896362 scopus 로고    scopus 로고
    • Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
    • Keulen W, Back NKT, van Wijk A, Boucher CA and Berkhout B, Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 71: 3346-3350, 1997.
    • (1997) J Virol , vol.71 , pp. 3346-3350
    • Keulen, W.1    Back, N.K.T.2    Van Wijk, A.3    Boucher, C.A.4    Berkhout, B.5
  • 77
    • 0029028067 scopus 로고
    • Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
    • Larder BA, Kemp SD and Harrigan PR, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699, 1995.
    • (1995) Science , vol.269 , pp. 696-699
    • Larder, B.A.1    Kemp, S.D.2    Harrigan, P.R.3
  • 78
    • 0029757751 scopus 로고    scopus 로고
    • Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
    • Back N, Nijhuis M, Keulen W, Boucher C, Oude Essink B, van Kuilenburg A, van Gennip A and Berkhout B, Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15: 4040-4049, 1996.
    • (1996) EMBO J , vol.15 , pp. 4040-4049
    • Back, N.1    Nijhuis, M.2    Keulen, W.3    Boucher, C.4    Oude Essink, B.5    Van Kuilenburg, A.6    Van Gennip, A.7    Berkhout, B.8
  • 81
    • 0029843986 scopus 로고    scopus 로고
    • Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
    • Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A and Larder BA, Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 70: 5930-5934, 1996.
    • (1996) J Virol , vol.70 , pp. 5930-5934
    • Harrigan, P.R.1    Kinghorn, I.2    Bloor, S.3    Kemp, S.D.4    Najera, I.5    Kohli, A.6    Larder, B.A.7
  • 82
    • 10244227943 scopus 로고    scopus 로고
    • An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine
    • Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E and Deacon NJ, An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 70: 8010-8018, 1996.
    • (1996) J Virol , vol.70 , pp. 8010-8018
    • Hooker, D.J.1    Tachedjian, G.2    Solomon, A.E.3    Gurusinghe, A.D.4    Land, S.5    Birch, C.6    Anderson, J.L.7    Roy, B.M.8    Arnold, E.9    Deacon, N.J.10
  • 83
    • 0028828540 scopus 로고
    • Development of zidovudine resistance mutations in patients receiving prolonged didanosine therapy
    • Demeter TM, Nawaz T, Morse S, Dolin R, Dexter A, Gerondelis P and Reichman RC, Development of zidovudine resistance mutations in patients receiving prolonged didanosine therapy. J Inject Dis 172: 1480-1485, 1995.
    • (1995) J Inject Dis , vol.172 , pp. 1480-1485
    • Demeter, T.M.1    Nawaz, T.2    Morse, S.3    Dolin, R.4    Dexter, A.5    Gerondelis, P.6    Reichman, R.C.7
  • 84
    • 0030892246 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility by changes in infected individuals receiving dideoxyinosine monotherapy
    • Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T and Merigan TC, Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility by changes in infected individuals receiving dideoxyinosine monotherapy. Antimicrob Agents Chemother 41: 757-762, 1997.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 757-762
    • Winters, M.A.1    Shafer, R.W.2    Jellinger, R.A.3    Mamtora, G.4    Gingeras, T.5    Merigan, T.C.6
  • 87
    • 0030048748 scopus 로고    scopus 로고
    • Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
    • Iversen AKN, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B and Merigan TC, Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70: 1086-1090, 1996.
    • (1996) J Virol , vol.70 , pp. 1086-1090
    • Iversen, A.K.N.1    Shafer, R.W.2    Wehrly, K.3    Winters, M.A.4    Mullins, J.I.5    Chesebro, B.6    Merigan, T.C.7
  • 94
    • 0013608982 scopus 로고    scopus 로고
    • Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance
    • St. Petersburg, Florida, USA, 25-28 June, Abstract No. 11
    • Kemp S and Bloor S, Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance. Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 11.
    • (1997) Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication
    • Kemp, S.1    Bloor, S.2
  • 96
    • 0029007143 scopus 로고
    • Drug resistance and heterogeneous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy
    • Shafer RW, Iversen AK, Winters MA, Aguiniga E, KatzenStein DA and Merigan TC, Drug resistance and heterogeneous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 172: 70-78, 1995.
    • (1995) J Infect Dis , vol.172 , pp. 70-78
    • Shafer, R.W.1    Iversen, A.K.2    Winters, M.A.3    Aguiniga, E.4    Katzenstein, D.A.5    Merigan, T.C.6
  • 97
    • 0028784434 scopus 로고
    • Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates
    • Ueno T, Shirasaka T and Mitsuya H, Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 270: 23605-23611, 1995.
    • (1995) J Biol Chem , vol.270 , pp. 23605-23611
    • Ueno, T.1    Shirasaka, T.2    Mitsuya, H.3
  • 98
    • 0031948662 scopus 로고    scopus 로고
    • Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multidideoxynucleoside resistance
    • Maeda Y, Venzon DJ and Mitsuya H, Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multidideoxynucleoside resistance. J Infect Dis 177: 1207-1213, 1998.
    • (1998) J Infect Dis , vol.177 , pp. 1207-1213
    • Maeda, Y.1    Venzon, D.J.2    Mitsuya, H.3
  • 99
    • 0013578284 scopus 로고    scopus 로고
    • Combination of the multidrug resistance mutation Q151 M/L and the AZT resistance mutation T215Y/F in the same HIV-1 reverse transcriptase is compatible with enzymatic activity. 2. Clinical science
    • Geneva, Switzerland, 28 June-3 July 1998, Monduzzi Editore, Bologna, Italy
    • Balzarini J, Dunkler A, Pelemans H, De Clercq E and Kleim J-P, Combination of the multidrug resistance mutation Q151 M/L and the AZT resistance mutation T215Y/F in the same HIV-1 reverse transcriptase is compatible with enzymatic activity. 2. Clinical science. Proceedings of The 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July 1998, pp. 319-323. Monduzzi Editore, Bologna, Italy, 1998.
    • (1998) Proceedings of the 12th World AIDS Conference , pp. 319-323
    • Balzarini, J.1    Dunkler, A.2    Pelemans, H.3    De Clercq, E.4    Kleim, J.-P.5
  • 100
    • 0029044698 scopus 로고
    • Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates
    • Mellors J, Bazmi H, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J and Mayers D, Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 39: 1087-1092, 1995.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1087-1092
    • Mellors, J.1    Bazmi, H.2    Schinazi, R.F.3    Roy, B.M.4    Hsiou, Y.5    Arnold, E.6    Weir, J.7    Mayers, D.8
  • 102
    • 0029792446 scopus 로고    scopus 로고
    • Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet
    • Tachedjian G, Mellors J, Bazmi H, Birch C and Mills J, zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol 70: 7171-7181, 1996.
    • (1996) J Virol , vol.70 , pp. 7171-7181
    • Tachedjian, G.1    Mellors, J.2    Bazmi, H.3    Birch, C.4    Mills, J.5
  • 103
    • 0026332220 scopus 로고
    • Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase
    • Prasad VR, Lowy I, de los Santos T, Chiang L and Goff SP, Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 88: 11363-11367, 1991.
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 11363-11367
    • Prasad, V.R.1    Lowy, I.2    De Los Santos, T.3    Chiang, L.4    Goff, S.P.5
  • 104
    • 0030070683 scopus 로고    scopus 로고
    • Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-Val or Ile and Val-75-Leu or Ile) HIV-1 mutants
    • Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, Arnold E and Riess G, Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-Val or Ile and Val-75-Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 93: 34-38, 1996.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 34-38
    • Kleim, J.P.1    Rosner, M.2    Winkler, I.3    Paessens, A.4    Kirsch, R.5    Hsiou, Y.6    Arnold, E.7    Riess, G.8
  • 105
    • 0031940767 scopus 로고    scopus 로고
    • A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer
    • Boyer PL, Gao H-Q and Hughes SH, A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 42: 447-452, 1998.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 447-452
    • Boyer, P.L.1    Gao, H.-Q.2    Hughes, S.H.3
  • 108
    • 0027214433 scopus 로고
    • Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells by combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy
    • Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J, Tarpley WG and De Clercq E, Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells by combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 67: 5353-5359, 1993.
    • (1993) J Virol , vol.67 , pp. 5353-5359
    • Balzarini, J.1    Karlsson, A.2    Pérez-Pérez, M.-J.3    Camarasa, M.-J.4    Tarpley, W.G.5    De Clercq, E.6
  • 112
    • 3042857907 scopus 로고    scopus 로고
    • Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266
    • Whistler, Canada, 3-6 July, Abstract No. 10
    • Winslow DL, Reid C, Garber S, Scamati H, Rayner M and Anton E, Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 10.
    • (1996) Fifth Int Workshop on HIV Drug Resistance
    • Winslow, D.L.1    Reid, C.2    Garber, S.3    Scamati, H.4    Rayner, M.5    Anton, E.6
  • 114
    • 0027278781 scopus 로고
    • Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents
    • Richman DD, Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 37: 1207-1213, 1993.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1207-1213
    • Richman, D.D.1
  • 115
    • 0026454435 scopus 로고
    • 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
    • Larder BA, 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 36: 2664-2669, 1992.
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 2664-2669
    • Larder, B.A.1
  • 117
    • 0027328082 scopus 로고
    • HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase
    • Balzarini J, Karlsson A, Pérez-Pérez M-J, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme A-M, Camarasa M-J and De Clercq E, HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192: 246-253, 1993.
    • (1993) Virology , vol.192 , pp. 246-253
    • Balzarini, J.1    Karlsson, A.2    Pérez-Pérez, M.-J.3    Vrang, L.4    Walbers, J.5    Zhang, H.6    Öberg, B.7    Vandamme, A.-M.8    Camarasa, M.-J.9    De Clercq, E.10
  • 120
    • 0029079399 scopus 로고
    • Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives)
    • Balzarini J, Pérez-Pérez M-J, Vélazquez S, San-Félix A, Camarasa M-J, De Clercq E and Karlsson A, Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc Natl Acad Sci USA 92: 5470-5474, 1995.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 5470-5474
    • Balzarini, J.1    Pérez-Pérez, M.-J.2    Vélazquez, S.3    San-Félix, A.4    Camarasa, M.-J.5    De Clercq, E.6    Karlsson, A.7
  • 121
    • 0029809694 scopus 로고    scopus 로고
    • Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication
    • Balzarini J, Pelemans H, Aquaro S, Perno C-F, Witvrouw M, Schols D, De Clercq E and Karlsson A, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol Pharmacol 50: 394-401, 1996.
    • (1996) Mol Pharmacol , vol.50 , pp. 394-401
    • Balzarini, J.1    Pelemans, H.2    Aquaro, S.3    Perno, C.-F.4    Witvrouw, M.5    Schols, D.6    De Clercq, E.7    Karlsson, A.8
  • 122
    • 0029904239 scopus 로고    scopus 로고
    • Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus
    • Balzarini J, Brouwer WG, Dao DC, Osika EM and De Clercq E, Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother 40: 1454-1466, 1996.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 1454-1466
    • Balzarini, J.1    Brouwer, W.G.2    Dao, D.C.3    Osika, E.M.4    De Clercq, E.5
  • 123
    • 0028885715 scopus 로고
    • Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127
    • Zhang H, Vrang L, Backbro K, Lind P, Sahlberg C, Unge T and Öberg B, Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res 28: 331-342, 1995.
    • (1995) Antiviral Res , vol.28 , pp. 331-342
    • Zhang, H.1    Vrang, L.2    Backbro, K.3    Lind, P.4    Sahlberg, C.5    Unge, T.6    Öberg, B.7
  • 126
    • 0029011342 scopus 로고
    • Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains
    • Balzarini J, Brouwer WG, Felauer EE, De Clercq E and Karlsson A, Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res 27: 219-236, 1995.
    • (1995) Antiviral Res , vol.27 , pp. 219-236
    • Balzarini, J.1    Brouwer, W.G.2    Felauer, E.E.3    De Clercq, E.4    Karlsson, A.5
  • 127
    • 0003334866 scopus 로고
    • Phenotypic and genotypic analysis of atevirdine (ATV) susceptibility of HIV-1 isolates obtained from patients receiving ATV monotherapy in a phase I clinical trial (ACTG 187): Comparison to patients receiving combination therapy with ATV and zidovudine
    • Gaithersburg, Maryland, USA
    • Demeter L, Resnick L, Nawaz T, Timpone JG Jr, Batts D and Reichman RC, Phenotypic and genotypic analysis of atevirdine (ATV) susceptibility of HIV-1 isolates obtained from patients receiving ATV monotherapy in a phase I clinical trial (ACTG 187): Comparison to patients receiving combination therapy with ATV and zidovudine. Third Workshop on Viral Resistance, Gaithersburg, Maryland, USA, 1993.
    • (1993) Third Workshop on Viral Resistance
    • Demeter, L.1    Resnick, L.2    Nawaz, T.3    Timpone J.G., Jr.4    Batts, D.5    Reichman, R.C.6
  • 128
    • 0029125583 scopus 로고
    • Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s
    • Fan N, Rank KB, Evans DB, Thomas RC, Tarpley WG and Sharma SK, Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Lett 370: 59-62, 1995.
    • (1995) FEBS Lett , vol.370 , pp. 59-62
    • Fan, N.1    Rank, K.B.2    Evans, D.B.3    Thomas, R.C.4    Tarpley, W.G.5    Sharma, S.K.6
  • 133
    • 0028958591 scopus 로고
    • Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442
    • Seki M, Sadakata Y, Yuasa S and Baba M, Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem Chemother 6: 73-79, 1995.
    • (1995) Antiviral Chem Chemother , vol.6 , pp. 73-79
    • Seki, M.1    Sadakata, Y.2    Yuasa, S.3    Baba, M.4
  • 134
    • 0030860860 scopus 로고    scopus 로고
    • Cross-resistance analysis and molecular modeling of non-nucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus
    • Yang SS, Pattabiraman N, Gussio R, Pallansch L, Buckheit RW Jr and Bader JP, Cross-resistance analysis and molecular modeling of non-nucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus. Leukemia 11 (Suppl 3): 89-92, 1997.
    • (1997) Leukemia , vol.11 , Issue.SUPPL. 3 , pp. 89-92
    • Yang, S.S.1    Pattabiraman, N.2    Gussio, R.3    Pallansch, L.4    Buckheit R.W., Jr.5    Bader, J.P.6
  • 136
    • 0027381149 scopus 로고
    • Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives
    • Balzarini J, Karlsson A and De Clercq E, Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol Pharmacol 44: 694-701, 1993.
    • (1993) Mol Pharmacol , vol.44 , pp. 694-701
    • Balzarini, J.1    Karlsson, A.2    De Clercq, E.3
  • 137
    • 0013605804 scopus 로고    scopus 로고
    • Different mutational pathways of the HIV-1 RT gene are defined by alternative experimental protocols applied to generate in vitro resistance of HIV-1 to HBY 097
    • Whistler, Canada, 3-6 July, Abstract No. 15
    • Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A and Reiss G, Different mutational pathways of the HIV-1 RT gene are defined by alternative experimental protocols applied to generate in vitro resistance of HIV-1 to HBY 097. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 15.
    • (1996) Fifth Int Workshop on HIV Drug Resistance
    • Kleim, J.P.1    Winkler, I.2    Rosner, M.3    Kirsch, R.4    Rubsamen-Waigmann, H.5    Paessens, A.6    Reiss, G.7
  • 138
    • 0030926748 scopus 로고    scopus 로고
    • In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure on the nonnucleoside reverse transcriptase inhibitor HBY 097
    • Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A and Reiss G, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure on the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 231: 112-118, 1997.
    • (1997) Virology , vol.231 , pp. 112-118
    • Kleim, J.P.1    Winkler, I.2    Rosner, M.3    Kirsch, R.4    Rubsamen-Waigmann, H.5    Paessens, A.6    Reiss, G.7
  • 139
    • 0028187436 scopus 로고
    • Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection
    • Vandamme A-M, Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection. Verh K Acad Geneeskd Belg 56: 231-265, 1994.
    • (1994) Verh K Acad Geneeskd Belg , vol.56 , pp. 231-265
    • Vandamme, A.-M.1
  • 140
    • 0032437454 scopus 로고    scopus 로고
    • The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
    • De Clercq E, The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38: 153-179, 1998.
    • (1998) Antiviral Res , vol.38 , pp. 153-179
    • De Clercq, E.1
  • 141
    • 0027524005 scopus 로고
    • Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl] -3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′, 2′-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type-1-specific non-nucleoside analogues
    • Balzarini J, Velazquez S, San-Félix A, Karlsson A, Pérez-Pérez M-J, Camarasa MJ and De Clercq E, Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′,2′-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type-1-specific non-nucleoside analogues. Mol Pharmacol 43: 109-114, 1993.
    • (1993) Mol Pharmacol , vol.43 , pp. 109-114
    • Balzarini, J.1    Velazquez, S.2    San-Félix, A.3    Karlsson, A.4    Pérez-Pérez, M.-J.5    Camarasa, M.J.6    De Clercq, E.7
  • 142
    • 0027202617 scopus 로고
    • Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tertbutyldimethylsilyl)-3′-spiro-5′- (4′-amino-1′,2′-oxathiole-2′,2′-dioxide)] -β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors
    • Balzarini J, Karlsson A, Vandamme A-M, Pérez-Pérez M-J, Zhang H, Vrang L, Öberg B, Bäckbro K, Unge T, San-Félix A, Velázquez S, Camarasa MJ and De Clercq E, Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tertbutyldimethylsilyl)-3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′,2′-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. Proc Natl Acad Sci USA 90: 6952-6956, 1993.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 6952-6956
    • Balzarini, J.1    Karlsson, A.2    Vandamme, A.-M.3    Pérez-Pérez, M.-J.4    Zhang, H.5    Vrang, L.6    Öberg, B.7    Bäckbro, K.8    Unge, T.9    San-Félix, A.10    Velázquez, S.11    Camarasa, M.J.12    De Clercq, E.13
  • 143
    • 0028940526 scopus 로고
    • Oxathiin carboxanilide derivatives: A class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs
    • Balzarini J, Jonckheere H, Harrison WA, Dao DC, Anné J, De Clercq E and Karlsson A, Oxathiin carboxanilide derivatives: A class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem Chemother 6: 169-178, 1995.
    • (1995) Antiviral Chem Chemother , vol.6 , pp. 169-178
    • Balzarini, J.1    Jonckheere, H.2    Harrison, W.A.3    Dao, D.C.4    Anné, J.5    De Clercq, E.6    Karlsson, A.7
  • 148
    • 0026579394 scopus 로고
    • In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase
    • Mellors JW, Dutchman GE, Im JG-J, Tramontane E, Winkler SR and Cheng Y-C, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 41: 446-451, 1992.
    • (1992) Mol Pharmacol , vol.41 , pp. 446-451
    • Mellors, J.W.1    Dutchman, G.E.2    Im, J.G.-J.3    Tramontane, E.4    Winkler, S.R.5    Cheng, Y.-C.6
  • 149
    • 0026318387 scopus 로고
    • Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
    • Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S and Griffin J, Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88: 11241-11245, 1991.
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 11241-11245
    • Richman, D.1    Shih, C.-K.2    Lowy, I.3    Rose, J.4    Prodanovich, P.5    Goff, S.6    Griffin, J.7
  • 150
    • 0029774789 scopus 로고    scopus 로고
    • Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogues: Evaluation of variables in the drug resistance selection process
    • Kinjerski TL, Pallansch LA and Buckheit RW Jr, Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogues: Evaluation of variables in the drug resistance selection process. Antiviral Chem Chemother 7: 261-269, 1996.
    • (1996) Antiviral Chem Chemother , vol.7 , pp. 261-269
    • Kinjerski, T.L.1    Pallansch, L.A.2    Buckheit R.W., Jr.3
  • 151
    • 0027376921 scopus 로고
    • Viral resistance to the thiazolo-isoindolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
    • Maass G, Immendoerfer U, Koening B, Leser U, Mueller B, Goody R and Pfaff E, Viral resistance to the thiazolo-isoindolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 2612-2617, 1993.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 2612-2617
    • Maass, G.1    Immendoerfer, U.2    Koening, B.3    Leser, U.4    Mueller, B.5    Goody, R.6    Pfaff, E.7
  • 152
    • 0028285185 scopus 로고
    • Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)RT HIV-1 mutants
    • Balzarini J, Karlsson A, Sardana VV, Emini EA, Camarasa M-J and De Clercq E, Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)rt HIV-1 mutants. Proc Natl Acad Sci USA 91: 6599-6603, 1994.
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 6599-6603
    • Balzarini, J.1    Karlsson, A.2    Sardana, V.V.3    Emini, E.A.4    Camarasa, M.-J.5    De Clercq, E.6
  • 153
    • 0013613209 scopus 로고
    • A drug resistance mutation (G190E) in the inhibitor binding pocket impairs both RNA-dependent DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase
    • Sardinia, Italy, 6-9 July, Abstract No. 2
    • Sharma SK, Fan N, Bank KB, Kopta LA, Olmsted RA, Poppe SM, Slade DE, Thomas RC and Tarpley WG, A drug resistance mutation (G190E) in the inhibitor binding pocket impairs both RNA-dependent DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 2.
    • (1995) Fourth Int Workshop on HIV Drug Resistance
    • Sharma, S.K.1    Fan, N.2    Bank, K.B.3    Kopta, L.A.4    Olmsted, R.A.5    Poppe, S.M.6    Slade, D.E.7    Thomas, R.C.8    Tarpley, W.G.9
  • 154
    • 0029897567 scopus 로고    scopus 로고
    • (Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes
    • Olmsted RA, Slade DE, Kopta LA, Poppe SM, Poel TJ, Newport SW, Rank KB, Biles C, Morge RA, Dueweke TJ, Yagi Y, Romero DL, Thomas RC, Sharma SK and Tarpley WG, (Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J Virol 70: 3698-3705, 1996.
    • (1996) J Virol , vol.70 , pp. 3698-3705
    • Olmsted, R.A.1    Slade, D.E.2    Kopta, L.A.3    Poppe, S.M.4    Poel, T.J.5    Newport, S.W.6    Rank, K.B.7    Biles, C.8    Morge, R.A.9    Dueweke, T.J.10    Yagi, Y.11    Romero, D.L.12    Thomas, R.C.13    Sharma, S.K.14    Tarpley, W.G.15
  • 157
    • 13344292642 scopus 로고
    • Genotypic analysis of HIV-1 isolates from patients receiving loviride alone or in combination with nucleoside reverse transcriptase inhibitor
    • Sardinia, Italy, 6-9 July, Abstract No. 34
    • Moeremans M, De Raeymaker M, Van den Broeck R, Stoffels P and Andries K, Genotypic analysis of HIV-1 isolates from patients receiving loviride alone or in combination with nucleoside reverse transcriptase inhibitor. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 34.
    • (1995) Fourth Int Workshop on HIV Drug Resistance
    • Moeremans, M.1    De Raeymaker, M.2    Van Den Broeck, R.3    Stoffels, P.4    Andries, K.5
  • 158
    • 0030879805 scopus 로고    scopus 로고
    • Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1
    • Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme A-M, Karlsson A, De Clercq E, Kleim J-P and Balzarini J, characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol 71: 8195-8203, 1997.
    • (1997) J Virol , vol.71 , pp. 8195-8203
    • Pelemans, H.1    Esnouf, R.2    Dunkler, A.3    Parniak, M.A.4    Vandamme, A.-M.5    Karlsson, A.6    De Clercq, E.7    Kleim, J.-P.8    Balzarini, J.9
  • 159
    • 0031806739 scopus 로고    scopus 로고
    • A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152
    • Pelemans H, Esnouf RM, Parniak MA, Vandamme A-M, De Clercq E and Balzarini J, A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J Gen Virol 79: 1347-1352, 1998.
    • (1998) J Gen Virol , vol.79 , pp. 1347-1352
    • Pelemans, H.1    Esnouf, R.M.2    Parniak, M.A.3    Vandamme, A.-M.4    De Clercq, E.5    Balzarini, J.6
  • 160
    • 0032502015 scopus 로고    scopus 로고
    • A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781
    • Balzarini J, Pelemans H, Esnouf R and De Clercq E, A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res Hum Retroviruses 14: 255-260, 1998.
    • (1998) AIDS Res Hum Retroviruses , vol.14 , pp. 255-260
    • Balzarini, J.1    Pelemans, H.2    Esnouf, R.3    De Clercq, E.4
  • 161
    • 0027231438 scopus 로고
    • A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
    • Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao Q, Chen SY, Stevenson M and Tarpley WG, A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 90: 4713-4717, 1993.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 4713-4717
    • Dueweke, T.J.1    Pushkarskaya, T.2    Poppe, S.M.3    Swaney, S.M.4    Zhao, Q.5    Chen, S.Y.6    Stevenson, M.7    Tarpley, W.G.8
  • 164
    • 0029593364 scopus 로고
    • Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: A paradigm for the cure of AIDS
    • De Clercq E and Balzarini J, Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: A paradigm for the cure of AIDS. Il Farmaco 50: 735-747, 1995.
    • (1995) Il Farmaco , vol.50 , pp. 735-747
    • De Clercq, E.1    Balzarini, J.2
  • 166
    • 0013626344 scopus 로고    scopus 로고
    • HIV-1 expressing the lamivudine-associated M184V mutation in reverse transcriptase (RT) shows increased susceptibility to adefovir and PMPA as well as decreased replication capacity in vitro
    • Lake Maggiore, Italy, 24-27 June, Abstract No. 34
    • Miller MD, Anton KE, Mulato AS, Lamy PD, Margot NA and Cherrington JM, HIV-1 expressing the lamivudine-associated M184V mutation in reverse transcriptase (RT) shows increased susceptibility to adefovir and PMPA as well as decreased replication capacity in vitro. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 34.
    • (1998) Second Int Workshop on HIV Drug Resistance and Treatment Strategies
    • Miller, M.D.1    Anton, K.E.2    Mulato, A.S.3    Lamy, P.D.4    Margot, N.A.5    Cherrington, J.M.6
  • 167
    • 0013582158 scopus 로고    scopus 로고
    • Resistance profiles to non-nucleoside reverse transcriptase inhibitors determined using a novel phenotypic drug susceptibility assay for HIV-1: Role of mutations at amino acids 225 and 236
    • Cold Spring Harbor, New York, USA, 26-31 May, Abstract
    • Lie YS, Winslow G, Limoli K, Parkin N, Wrin T, Tian T, Smith D, Petropoulos CJ and Whitcomb JM, Resistance profiles to non-nucleoside reverse transcriptase inhibitors determined using a novel phenotypic drug susceptibility assay for HIV-1: Role of mutations at amino acids 225 and 236. 1988 Meeting on Retroviruses, Cold Spring Harbor, New York, USA, 26-31 May 1998, Abstract p. 365.
    • (1998) 1988 Meeting on Retroviruses , pp. 365
    • Lie, Y.S.1    Winslow, G.2    Limoli, K.3    Parkin, N.4    Wrin, T.5    Tian, T.6    Smith, D.7    Petropoulos, C.J.8    Whitcomb, J.M.9
  • 168
    • 0027373308 scopus 로고
    • High-level resistance to (-) enantiomeric 2′deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
    • Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA and Cameron JM, High-level resistance to (-) enantiomeric 2′deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 2231-2234, 1993.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 2231-2234
    • Boucher, C.A.B.1    Cammack, N.2    Schipper, P.3    Schuurman, R.4    Rouse, P.5    Wainberg, M.A.6    Cameron, J.M.7
  • 169
    • 0026454435 scopus 로고
    • 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
    • Larder BA, 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 36: 2664-2669, 1992.
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 2664-2669
    • Larder, B.A.1
  • 173
    • 0030830881 scopus 로고    scopus 로고
    • Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine
    • Balzarini J, Pelemans H, Riess G, Roesner M, Winkler I, De Clercq E and Kleim J-P, Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. J Infect Dis 176: 1392-1397, 1997.
    • (1997) J Infect Dis , vol.176 , pp. 1392-1397
    • Balzarini, J.1    Pelemans, H.2    Riess, G.3    Roesner, M.4    Winkler, I.5    De Clercq, E.6    Kleim, J.-P.7
  • 174
    • 0032030658 scopus 로고    scopus 로고
    • Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azido-thymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine)
    • Balzarini J, Pelemans H, Riess E, Roesner M, Winkler I, De Clercq E and Kleim J-P, Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azido-thymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem Pharmacol 55: 617-625, 1998.
    • (1998) Biochem Pharmacol , vol.55 , pp. 617-625
    • Balzarini, J.1    Pelemans, H.2    Riess, E.3    Roesner, M.4    Winkler, I.5    De Clercq, E.6    Kleim, J.-P.7
  • 175
    • 0030750548 scopus 로고    scopus 로고
    • Inhibition of replication of human immunodeficiency virus in primary monocyte-macrophages by different antiviral drugs, and comparative efficacy in lymphocytes
    • Aquaro S, Perno C-F, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N and Caliò R, Inhibition of replication of human immunodeficiency virus in primary monocyte-macrophages by different antiviral drugs, and comparative efficacy in lymphocytes. J Leukoc Biol 62: 138-143, 1997.
    • (1997) J Leukoc Biol , vol.62 , pp. 138-143
    • Aquaro, S.1    Perno, C.-F.2    Balestra, E.3    Balzarini, J.4    Cenci, A.5    Francesconi, M.6    Panti, S.7    Serra, F.8    Villani, N.9    Caliò, R.10
  • 176
    • 0028019710 scopus 로고
    • Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
    • Gao W-Y, Johns DG and Mitsuya H, Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 46: 767-772, 1994.
    • (1994) Mol Pharmacol , vol.46 , pp. 767-772
    • Gao, W.-Y.1    Johns, D.G.2    Mitsuya, H.3
  • 178
    • 23444436383 scopus 로고
    • Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds
    • Malley SD, Grange JM, Hamedi-Sangsari F and Vila JR, Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 343: 1292, 1994.
    • (1994) Lancet , vol.343 , pp. 1292
    • Malley, S.D.1    Grange, J.M.2    Hamedi-Sangsari, F.3    Vila, J.R.4
  • 179
    • 0029086336 scopus 로고
    • Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus
    • Gao W-Y, Johns DG, Chokekijchai S and Mitsuya H, Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 92: 8333-8337, 1995.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 8333-8337
    • Gao, W.-Y.1    Johns, D.G.2    Chokekijchai, S.3    Mitsuya, H.4
  • 180
    • 0027377963 scopus 로고
    • Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
    • Gao W-Y, Cara A, Gallo RC and Lori F, Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 90: 8925-8928, 1993.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 8925-8928
    • Gao, W.-Y.1    Cara, A.2    Gallo, R.C.3    Lori, F.4
  • 181
    • 0027976787 scopus 로고
    • Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
    • Meyerhans A, Vartanian J-P, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S and Wain-Hobson S, Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 68: 535-540, 1994.
    • (1994) J Virol , vol.68 , pp. 535-540
    • Meyerhans, A.1    Vartanian, J.-P.2    Hultgren, C.3    Plikat, U.4    Karlsson, A.5    Wang, L.6    Eriksson, S.7    Wain-Hobson, S.8
  • 182
    • 0026863789 scopus 로고
    • DNA precursor asymmetries, replication fidelity, and variable genome evolution
    • Matthews CK and Ji J, DNA precursor asymmetries, replication fidelity, and variable genome evolution. Bioessays 14: 295-301, 1992.
    • (1992) Bioessays , vol.14 , pp. 295-301
    • Matthews, C.K.1    Ji, J.2
  • 183
    • 0013676224 scopus 로고    scopus 로고
    • Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates
    • Lake Maggiore, Italy, 24-27 June, Abstract No. 3
    • Palmer S, Shafer R and Merigan TC, Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 3.
    • (1998) Second Int Workshop on HIV Drug Resistance and Treatment Strategies
    • Palmer, S.1    Shafer, R.2    Merigan, T.C.3
  • 185
    • 0027399054 scopus 로고
    • Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control
    • Hengstschläger M, Denk C and Wawra E, Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett 321: 237-240, 1993.
    • (1993) FEBS Lett , vol.321 , pp. 237-240
    • Hengstschläger, M.1    Denk, C.2    Wawra, E.3
  • 187
    • 0024850371 scopus 로고
    • Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells
    • Karlsson A, Reichard P and Eckstein F, Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells. Eur J Biochem 186: 689-694, 1989.
    • (1989) Eur J Biochem , vol.186 , pp. 689-694
    • Karlsson, A.1    Reichard, P.2    Eckstein, F.3
  • 188
    • 0031054871 scopus 로고    scopus 로고
    • Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea
    • Palmer S and Cox S, Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother 41: 460-464, 1997.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 460-464
    • Palmer, S.1    Cox, S.2
  • 189
    • 0029933819 scopus 로고    scopus 로고
    • 1-Year follow-up of the use of hydroxycarbamide and didanosine in HIV infection
    • Vila J, Biron F, Nugier F, Vallet T and Peyramond D, 1-Year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 348: 203-204, 1996.
    • (1996) Lancet , vol.348 , pp. 203-204
    • Vila, J.1    Biron, F.2    Nugier, F.3    Vallet, T.4    Peyramond, D.5
  • 190
    • 0031004424 scopus 로고    scopus 로고
    • Long-term suppression of HIV-1 by hydroxyurea and didanosine
    • Lori F, Jessen H, Foli A and Lisziewicz L, Long-term suppression of HIV-1 by hydroxyurea and didanosine. J Am Med Assoc 277: 1437-1438, 1997.
    • (1997) J Am Med Assoc , vol.277 , pp. 1437-1438
    • Lori, F.1    Jessen, H.2    Foli, A.3    Lisziewicz, L.4
  • 195
    • 0032524983 scopus 로고    scopus 로고
    • Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus
    • Johns DG and Gao W-Y, Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 55: 1551-1556, 1998.
    • (1998) Biochem Pharmacol , vol.55 , pp. 1551-1556
    • Johns, D.G.1    Gao, W.-Y.2
  • 196
    • 0003237094 scopus 로고    scopus 로고
    • Salvage of multi-drug resistant HIV infections with D4T/3TC/hydroxyurea
    • Geneva, Switzerland, 28 June-3 July Abstract No. 288*/12205
    • Milles S, Winters RE and Ruane P, Salvage of multi-drug resistant HIV infections with D4T/3TC/hydroxyurea. 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July 1998, Abstract No. 288*/12205.
    • (1998) 12th World AIDS Conference
    • Milles, S.1    Winters, R.E.2    Ruane, P.3
  • 197
    • 0023502171 scopus 로고
    • 2′,3′-Dideoxycytidine: Regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis
    • Balzarini J, Cooney DA, Dalai M, Kang G-J, Cupp JE, De Clercq E, Broder S and Johns DG, 2′,3′-Dideoxycytidine: Regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 32: 798-806, 1987.
    • (1987) Mol Pharmacol , vol.32 , pp. 798-806
    • Balzarini, J.1    Cooney, D.A.2    Dalai, M.3    Kang, G.-J.4    Cupp, J.E.5    De Clercq, E.6    Broder, S.7    Johns, D.G.8
  • 198
    • 0029895282 scopus 로고    scopus 로고
    • 2′,3′-Didehydro-3′-deoxythymidine: Regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis
    • Ahluwalia GS, Gao W-Y, Mitsuya H and Johns DG, 2′,3′-Didehydro-3′-deoxythymidine: Regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Mol Pharmacol 50: 160-165, 1996.
    • (1996) Mol Pharmacol , vol.50 , pp. 160-165
    • Ahluwalia, G.S.1    Gao, W.-Y.2    Mitsuya, H.3    Johns, D.G.4
  • 199
    • 0023636684 scopus 로고
    • Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro
    • Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E and Desmyter J, Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 31: 1613-1617, 1987.
    • (1987) Antimicrob Agents Chemother , vol.31 , pp. 1613-1617
    • Baba, M.1    Pauwels, R.2    Balzarini, J.3    Herdewijn, P.4    De Clercq, E.5    Desmyter, J.6
  • 200
    • 0024391709 scopus 로고
    • Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo
    • Balzarini J, Herdewijn P and De Clercq E, Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo. Antiviral Res 11: 161-172, 1989.
    • (1989) Antiviral Res , vol.11 , pp. 161-172
    • Balzarini, J.1    Herdewijn, P.2    De Clercq, E.3
  • 201
    • 0025201597 scopus 로고
    • Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside
    • Balzarini J, Naesens L, Robins MJ and De Clercq E, Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J Acquir Immune Defic Syndr 3: 1140-1147, 1990.
    • (1990) J Acquir Immune Defic Syndr , vol.3 , pp. 1140-1147
    • Balzarini, J.1    Naesens, L.2    Robins, M.J.3    De Clercq, E.4
  • 202
    • 0025880937 scopus 로고
    • Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus
    • Balzarini J, Lee C-K, Herdewijn P and De Clercq E, Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 266: 21509-21514, 1991.
    • (1991) J Biol Chem , vol.266 , pp. 21509-21514
    • Balzarini, J.1    Lee, C.-K.2    Herdewijn, P.3    De Clercq, E.4
  • 204
    • 0025773889 scopus 로고
    • Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine
    • Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S and Johns DG, Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 40: 118-124, 1991.
    • (1991) Mol Pharmacol , vol.40 , pp. 118-124
    • Hartman, N.R.1    Ahluwalia, G.S.2    Cooney, D.A.3    Mitsuya, H.4    Kageyama, S.5    Fridland, A.6    Broder, S.7    Johns, D.G.8
  • 205
    • 0024435381 scopus 로고
    • Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells
    • Johnson MA and Fridland A, Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol 36: 291-295, 1989.
    • (1989) Mol Pharmacol , vol.36 , pp. 291-295
    • Johnson, M.A.1    Fridland, A.2
  • 209
    • 0031012898 scopus 로고    scopus 로고
    • Reverse transcriptase fidelity and HIV-1 variation
    • Preston BD, Reverse transcriptase fidelity and HIV-1 variation. Science 275: 228-229, 1997.
    • (1997) Science , vol.275 , pp. 228-229
    • Preston, B.D.1
  • 210
    • 0031980213 scopus 로고    scopus 로고
    • Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro
    • Drosopoulos WC and Prasad VR, Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. J Virol 72: 4224-4230, 1998.
    • (1998) J Virol , vol.72 , pp. 4224-4230
    • Drosopoulos, W.C.1    Prasad, V.R.2
  • 213
    • 0028952146 scopus 로고
    • HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy
    • Coffin JM, HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 267: 483-489, 1995.
    • (1995) Science , vol.267 , pp. 483-489
    • Coffin, J.M.1
  • 218
    • 0032549742 scopus 로고    scopus 로고
    • Exploring how to get at - And eradicate - Hidden HIV
    • Cohen J, Exploring how to get at - and eradicate - hidden HIV. Science 279: 1854-1855, 1998.
    • (1998) Science , vol.279 , pp. 1854-1855
    • Cohen, J.1
  • 219
    • 0032546919 scopus 로고    scopus 로고
    • Toward HIV eradication or remission: The tasks ahead
    • Ho DD, Toward HIV eradication or remission: The tasks ahead. Science 280: 1866-1867, 1998.
    • (1998) Science , vol.280 , pp. 1866-1867
    • Ho, D.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.